Loading
Life sciences · Journal article
Frontiers in Cell and Developmental Biology · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Prostate cancer bone metastasis is increasingly understood as a dynamic interaction between disseminated tumor cells and a bone microenvironment that can be remodeled before, during, and after tumor-cell arrival. Extracellular vesicles (EVs), including preparations described as exosomes, may contribute to this communication by transferring proteins, lipids, and nucleic acids to bone-resident, stromal, and immune cells. Among these cargos, microRNAs (miRNAs) are attractive candidates because they can regulate multiple transcripts and cellular phenotypes. In this narrative review, we examine evidence linking EV-associated miRNAs to osteoclastogenesis, osteoblast-lineage remodeling, bone-marrow mesenchymal stromal-cell function, immune regulation, and reciprocal communication between bone-resident cells and prostate cancer cells. We distinguish evidence from pre-metastatic conditioning, metastatic colonization, and established metastatic growth, and we separate miRNA-specific causal evidence from associations or effects attributable to broader EV cargo. We also evaluate circulating EV-associated miRNAs as candidate biomarkers and discuss experimental therapeutic strategies, including inhibition of EV release, miRNA mimics or inhibitors, and engineered delivery systems. Current evidence supports a contributory role for EV-associated miRNAs in prostate cancer-bone communication, but the specificity of vesicle preparations, the causal contribution of individual miRNAs, and the existence of a bona fide bone pre-metastatic niche remain incompletely established. Standardized EV characterization, mechanistic validation, prospective clinical studies, and bone-targeted delivery systems are therefore required before these candidates can be translated into reliable biomarkers or therapies.